Kiniksa Pharmaceuticals Stock Quote KNSA - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

21.81

Bid

21.61

Ask

26.50

Volume

0.00 Day's Range 0.00

15.05 52 Week Range 28.15

Market Cap

1.575B

Previous Close

21.81

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

373,292

Shares Outstanding

72,201,565

Dividend Yield

PE Ratio

111.79

Earnings Per Share (EPS)

0.2

Revenue

270.26M

Net Profit

14.08M

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurre... Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.kiniksa.com

Headquarters

London, Gbr

Founded

Kiniksa Pharmaceuticals International PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KNSA. The last closing price for Kiniksa Pharmaceuticals was $21.81. Over the last year, Kiniksa Pharmaceuticals shares have traded in a share price range of $ 15.05 to $ 28.15.

Kiniksa Pharmaceuticals currently has 72,201,565 shares outstanding. The market capitalization of Kiniksa Pharmaceuticals is $1.57 billion. Kiniksa Pharmaceuticals has a price to earnings ratio (PE ratio) of 111.79.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $410 - $420 million ––...

Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

– National campaign to elevate experiences from the recurrent pericarditis community and empower patients to seek care – LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals...

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.2	-5.21512385919	23.01	23.515	21.705	310242	22.74858275	CS
4	-4.8	-18.0383314543	26.61	28.15	20.2552	349334	23.69276977	CS
12	-4.7	-17.729158808	26.51	28.15	20.2552	373292	24.86542169	CS
26	2.01	10.1515151515	19.8	28.15	17.38	406792	23.44673896	CS
52	5.91	37.1698113208	15.9	28.15	15.05	408545	21.10960647	CS
156	8.39	62.5186289121	13.42	28.15	7.36	390904	16.05882589	CS
260	15.36	238.139534884	6.45	33	6.28	386953	16.37988073	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BENFBeneficient	$ 2.40 (92.00%)	31.47M
GREEGreenidge Generation Holdings Inc	$ 3.94 (59.51%)	9.22M
IBGInnovation Beverage Group Limited	$ 1.70 (57.57%)	2.21M
RBBRBB Bancorp	$ 35.01 (41.00%)	314
GANXGain Therapeutics Inc	$ 2.40 (37.54%)	337
TFFPTFF Pharmaceuticals Inc	$ 0.473 (-70.44%)	315.05k
TSSITSS Inc	$ 8.20 (-31.55%)	46.43k
PGCPeapack Gladstone Financial Corporation	$ 25.01 (-31.39%)	25
HSTMHealthStream Inc	$ 22.00 (-31.31%)	100
HTBIHomeTrust Bancshares Inc	$ 26.20 (-29.85%)	104
BENFBeneficient	$ 2.40 (92.00%)	31.47M
ELABElevai Labs Inc	$ 0.0239 (-8.78%)	30.27M
GREEGreenidge Generation Holdings Inc	$ 3.94 (59.51%)	9.22M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 17.61 (0.00%)	7.04M
QUBTQuantum Computing Inc	$ 3.21 (-27.05%)	5.12M